Lisa Broad is Vice President Neuroscience at Eli Lilly and Company.
A physiologist/pharmacologist by training with more than 25 years research experience in academia and industry. Extensive knowledge of drug discovery and development, ranging from target identification through to clinical proof of concept. Over 20 years’ experience within the Neuroscience therapeutic area, developing symptomatic and disease modifying therapies for patients with chronic pain, migraine and neurodegenerative diseases.
Currently Vice President, responsible for Neurodegeneration Discovery Research at Eli Lilly and Company and Managing Director of Lilly Research Labs in the UK. Prior to joining Industry, completed post-doctoral studies at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA and the University of Cambridge; receiving a doctorate from the University of Cambridge.
